WHAT IS CLAIMED IS:

1. Use of Compound A in the manufacture of a medicament for treating a depressive disorder in a human in need thereof;

wherein Compound A is *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.

2. The use of claim 1, wherein treating the depressive disorder comprises enhancing the opening of a Kv7 potassium channel in the human.

3. Use of Compound A in the manufacture of a medicament for enhancing the opening of a Kv7 potassium channel in a human;

wherein Compound A is *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide; and

wherein the human has a depressive disorder.

4. The use of claim 2 or claim 3, wherein the Kv7 potassium channel is one or more of Kv7.2, Kv7.3, Kv7.4, or Kv7.5.

5. The use of claim 4, wherein enhancing the opening of a Kv7 potassium channel is selective for enhancing the opening of one or more of Kv7.2, Kv7.3, Kv7.4, or Kv7.5 over Kv7.1.

6. The use of claim 2 or 3, wherein enhancing the opening of a Kv7 potassium channel comprises opening of the Kv7.2/Kv7.3 (KCNQ2/3) potassium channel.

7. The use of any one of claims 1-6, wherein the depressive disorder is major depressive disorder (MDD), disruptive mood dysregulation disorder, persistent depressive disorder, bipolar spectrum disorder, postpartum depression, premenstrual dysphoric disorder (PMDD), seasonal affective disorder (SAD), atypical depression, treatment-resistant depression (TRD), depression associated with agitation or anxiety, adjustment disorder with depressed mood, prolonged depressive reaction, or a combination thereof.

8. The use of any one of claims 1-7, wherein the depressive disorder is major depressive disorder (MDD).

9. The use of any one of claims 1-7, wherein the depressive disorder is bipolar spectrum disorder.

10. The use of claim 9, wherein the bipolar spectrum disorder is treatment-resistant bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, and bipolar disorder not otherwise specified.

11. The use of any one of claims 1-10, wherein Compound A is orally administered to the human.

12. The use of any one of claims 1-11, wherein Compound A is orally administered to the human under fed conditions.

13. The use of any one of claims 1-12, wherein Compound A is orally administered to the human between about 4 hours prior to about 4 hours after eating food.

14. The use of any one of claims 1-13, wherein Compound A is orally administered to the human between about 30 minutes prior to eating food to about 2 hours after eating food.

15. The use of any one of claims 1-14, wherein Compound A is orally administered to the human while eating food or within 15 minutes after eating food.

16. The use of any one of claims 13-15, wherein the food is a meal.

17. The use of any one of claims 1-16, wherein Compound A is administered at a dose of 2 to 200 mg to the human.

18. The use of any one of claims 1-17, wherein Compound A is administered at a dose of 2 to 100 mg to the human.

19. The use of any one of claims 1-18, wherein Compound A is administered at a dose of 5 to 50 mg to the human.

20. The use of any one of claims 1-19, wherein Compound A is administered at a dose of 10 to 30 mg to the human.

21. The use of any one of claims 1-20, wherein Compound A is administered at a dose of 5, 10, 15, 20,25 or 30 mg to the human.

22. The use of any one of claims 1-21, wherein Compound A is administered at a dose of at least 2-100 mg per day.

23. The use of any one of claims 1-22, wherein Compound A is administered at a dose of at least 5-50 mg per day.

24. The use of any one of claims 1-23, wherein Compound A is administered at a dose of at least 10-30 mg per day.

25. The use of any one of claims 1-24, wherein Compound A is administered as a single dose per day.

26. The use of any one of claims 1-25, wherein Compound A is orally administered as a single dose of 2-100 mg per day.

27. The use of any one of claims 1-26, wherein Compound A is orally administered as a single dose of 5-50 mg per day.

28. The use of any one of claims 1-27, wherein Compound A is orally administered as a single dose of 10-30 mg per day.

29. The use of any one of claims 1-28, wherein Compound A is administered at a dose of 10, 15, 20, 25, or 30 mg per day.

30. The use of any one of claims 1-29, wherein Compound A is administered at a dose of 0.05-2.0 mg/kg to the human.

31. The use of any one of claims 1-30, wherein Compound A is administered at a dose of 0.1-1.0 mg/kg to the human.

32. The use of any one of claims 1-31, wherein Compound A is administered at a dose of 0.2-0.5 mg/kg to the human.

33. The use of any one of claims 1-32, wherein Compound A reduces the number of depressive episodes and/or reduce of the severity of depressive episodes.